Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Jane Osbourn OBE, CSO of Alchemab and Professor Paul Kellam, VP Infectious diseases and vaccines at Kymab, will discuss their collaborative roles in the BioIndustry Association's Antibody Taskforce to identify and develop new therapeutics in the fight against COVID-19.

Flyer for the Industry Insight Seminar on 6th April 2021 featuring the BIA antibody taskforce

The BIA Antibody Taskforce is a world-leading consortium of biotech companies, charities and academia experts based across the UK who share a joint commitment to help fight the COVID-19 pandemic. Contributing their expertise and specialist resources, the team is working together to rapidly identify the most promising antibodies with the potential to positively impact the treatment of those affected by this devastating virus.

The goal of the Taskforce is to develop an antibody-based treatment for patients with COVID-19, which could also potentially work as a preventative therapy for high-risk individuals and complement the current vaccination strategy. As part of a global hub for the life sciences, the UK BIA Antibody Taskforce wants to truly make a difference to people's lives.

Click here to register

For more information on the BIA Antibody Taskforce, click here.